-Esperion Therapeutics hopes to bring their LDL-c lowering drug, Bempedoic Acid, to the market -Their latest data shows a slight increase in patient deaths, which has pushed the stock lower, but I don't believe this to be meaningful -PCSK9 inhibitors are very expensive, and ESPR believes they can charge a lower price and attract a large number of patients -The FDA may require a large-scale cardiovascular outcomes trial that will delay full approval of BA -Follow me @matthewlepoire Relevant links: http://investor.esperion.com/static-files/88da95da-bb52-4e7e-a9dd-1d52e70f3a6b https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4719137/pdf/ahdb-08-483.pdf https://www.nature.com/news/the-fda-chief-must-not-be-a-proxy-for-industry-1.21661 This is not investment/trading advice